{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiba4emysqgm2ocjmsmfmn56siq24iyj33gdbrbumt3tjxeevf3vgq",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mp3wo3polse2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreibfj72n7je7k54uckhk65cyeori25yp34lder4owaxkbxu2ksjaj4"
    },
    "mimeType": "image/jpeg",
    "size": 104977
  },
  "path": "/2026/06/24/regenxbio-duchenne-gene-therapy-fda-submission/?utm_campaign=rss",
  "publishedAt": "2026-06-24T11:55:38.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "biotechnology",
    "drug development",
    "rare disease",
    "STAT+"
  ],
  "textContent": "Regenxbio plans to submit its Duchenne gene therapy for FDA approval, just a month after it said that regulators wanted to see another trial.",
  "title": "STAT+: Wagering on FDA changes, Regenxbio will submit Duchenne gene therapy for approval",
  "updatedAt": "2026-06-24T14:07:42.000Z"
}